1
|
Zhao JZ, Lu YC, Wang YM, Xiao BL, Li HY, Lee SC, Wang LJ. Association between diabetes and acute lymphocytic leukemia, acute myeloid leukemia, non-Hopkin lymphoma, and multiple myeloma. Int J Diabetes Dev Ctries 2021. [DOI: 10.1007/s13410-021-01021-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Abstract
Objective
Diabetes increases the risk for cancers. However, whether it is associated with hematologic malignancies is not clear. The present study investigated the association between diabetes and acute lymphocytic leukemia (ALL), acute myeloid leukemia (ML), non-Hopkin lymphoma (NHL), and multiple myeloma (MM).
Methods
Newly diagnosed adult cancer patients were recruited consecutively from our clinical database. Peoples from a local enterprise were recruited to create a small-scale population-based dataset. We compared the diabetes prevalence between the cancer patients and the local people; an increase in diabetes prevalence in the cancer patients suggests an association between diabetes and the cancer(s).
Results
We found that the prevalence of diabetes was 19.7%, 21.3%, 12.5%, and 12.0% in ALL, AML, NHL, and MM, respectively, which was higher than that (9.1%) in the local people. Despite that there were more male than female cancer patients, there were more female than male diabetic patients. The increase in diabetes prevalence occurred in ALL and NHL patients aged 18 to 39 years old as well as in AML patients over 40. In MM patients, the increase in diabetes prevalence (18.6%) occurred only in females. Approximately 70% of the diabetic patients were undiagnosed before the diagnosis of the blood cancer. Approximately half of the pre-existing diabetic patients had anti-diabetic treatment, with over 70% of them still had poor glycemic control.
Conclusions
Our results suggest that diabetes is associated with ALL, AML, NHL, and MM, at least in adult patients.
Collapse
|
2
|
Yang WC, Lin SF, Su YC. Multiple Myeloma: Personalised Medicine Based on Pathogenesis. EUROPEAN MEDICAL JOURNAL 2018. [DOI: 10.33590/emj/10312856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Multiple myeloma is increasingly being recognised as more than one disease, characterised by marked cytogenetic, molecular, and proliferative heterogeneity. The prognosis is widely varied, ranging from low to very high-risk, based on cytogenetic and molecular studies. Although novel agents, such as proteasome inhibitors and immunomodulators, have been developed, which have improved treatment responses and disease prognosis, multiple myeloma remains an incurable disease. Based on highly sensitive detection tools, such as gene expression profiling and next generation sequence analysis, and the understanding of the pathogenesis of multiple myeloma, many potential agents, including monoclonal antibodies, drug-conjugated antibodies, drugs targeted to molecular abnormalities, microRNA inhibitors or mimics, and immune therapies, such as chimeric antigen receptors T cells and anti-PD1 agents, can be considered personalised therapies. In this paper, multiple myeloma pathogenesis and potential molecular and immunotherapies are reviewed.
Collapse
Affiliation(s)
- Wen-Chi Yang
- Division of Hematology and Medical Oncology, Department of Internal Medicine, E-DA Hospital, Kaohsiung, Taiwan; School of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan
| | - Sheng-Fung Lin
- Division of Hematology and Medical Oncology, Department of Internal Medicine, E-DA Hospital, Kaohsiung, Taiwan
| | - Yu-Chieh Su
- Division of Hematology and Medical Oncology, Department of Internal Medicine, E-DA Hospital, Kaohsiung, Taiwan; School of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan
| |
Collapse
|
3
|
Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, Stefanikova Z, Pour L, Hajek R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med 2016; 14:150. [PMID: 27234807 PMCID: PMC4884414 DOI: 10.1186/s12967-016-0906-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 05/13/2016] [Indexed: 01/22/2023] Open
Abstract
Background The genome of multiple myeloma (MM) cells is extremely unstable, characterized by a complex combination of structure and numerical abnormalities. It seems that there are several “myeloma subgroups” which differ in expression profile, clinical manifestations, prognoses and treatment response. In our previous work, the list of 35 candidate genes with a known role in carcinogenesis and associated with centrosome structure/function was used as a display of molecular heterogeneity with an impact in myeloma pathogenesis. The current study was devoted to establish a risk stratification model based on the aforementioned candidate genes. Methods A total of 151 patients were included in this study. CD138+ cells were separated by magnetic-activated cell sorting (MACS). Gene expression profiling (GEP) and Interphase FISH with cytoplasmic immunoglobulin light chain staining (cIg FISH) were performed on plasma cells (PCs). All statistical analyses were performed using freeware R and its additional packages. Training and validation cohort includes 73 and 78 patients, respectively. Results We have finally established a model that includes 12 selected genes (centrosome associated gene pattern, CAGP) which appears to be an independent prognostic factor for MM stratification. We have shown that the new CAGP model can sub-stratify prognosis in patients without TP53 loss as well as in IMWG high risk patients’ group. Conclusions We assume that newly established risk stratification model complements the current prognostic panel used in multiple myeloma and refines the classification of patients in relation to the disease risks. This approach can be used independently as well as in combination with other factors. Electronic supplementary material The online version of this article (doi:10.1186/s12967-016-0906-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Fedor Kryukov
- Department of Haematooncology, Faculty of Medicine, University of Ostrava, Dvořákova 7, 702 00, Ostrava, Czech Republic. .,Department of Haematooncology, University Hospital Ostrava, 17.listopadu 1790, 708 52, Ostrava-Poruba, Czech Republic.
| | - Pavel Nemec
- Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
| | - Lenka Radova
- The Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
| | - Elena Kryukova
- Department of Haematooncology, Faculty of Medicine, University of Ostrava, Dvořákova 7, 702 00, Ostrava, Czech Republic.,Department of Haematooncology, University Hospital Ostrava, 17.listopadu 1790, 708 52, Ostrava-Poruba, Czech Republic
| | - Samuel Okubote
- Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
| | - Jiri Minarik
- Department of Internal Medicine, University Hospital Olomouc, I.P. Pavlova 185/6, 779 00, Olomouc, Czech Republic
| | - Zdena Stefanikova
- Department of Hematology and Blood Transfusion, University Hospital Bratislava, Antolská 11, 851 07, Bratislava, Slovak Republic
| | - Ludek Pour
- Department of Clinical Hematology, University Hospital Brno, Jihlavská 20, 625 00, Brno, Czech Republic
| | - Roman Hajek
- Department of Haematooncology, Faculty of Medicine, University of Ostrava, Dvořákova 7, 702 00, Ostrava, Czech Republic.,Department of Haematooncology, University Hospital Ostrava, 17.listopadu 1790, 708 52, Ostrava-Poruba, Czech Republic
| |
Collapse
|
4
|
Di Martino MT, Arbitrio M, Guzzi PH, Cannataro M, Tagliaferri P, Tassone P. Experimental treatment of multiple myeloma in the era of precision medicine. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2016. [DOI: 10.1080/23808993.2016.1142356] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|